E. Ohman J or Asset Management AB Purchases 1,430 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

E. Ohman J or Asset Management AB boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 13.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,740 shares of the pharmaceutical company's stock after buying an additional 1,430 shares during the period. E. Ohman J or Asset Management AB's holdings in Vertex Pharmaceuticals were worth $4,728,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in VRTX. Edgewood Management LLC increased its position in Vertex Pharmaceuticals by 7,876.3% in the 3rd quarter. Edgewood Management LLC now owns 1,546,370 shares of the pharmaceutical company's stock worth $719,186,000 after purchasing an additional 1,526,983 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Vertex Pharmaceuticals by 18.1% in the 3rd quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company's stock valued at $2,581,373,000 after buying an additional 851,054 shares in the last quarter. Wellington Management Group LLP increased its holdings in Vertex Pharmaceuticals by 17.2% in the third quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company's stock worth $2,231,858,000 after buying an additional 704,421 shares during the last quarter. Assenagon Asset Management S.A. raised its position in Vertex Pharmaceuticals by 169.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 839,672 shares of the pharmaceutical company's stock valued at $338,136,000 after acquiring an additional 528,029 shares in the last quarter. Finally, International Assets Investment Management LLC increased its stake in shares of Vertex Pharmaceuticals by 74,015.5% during the 3rd quarter. International Assets Investment Management LLC now owns 324,626 shares of the pharmaceutical company's stock worth $150,977,000 after purchasing an additional 324,188 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Trading Down 2.5 %

NASDAQ:VRTX traded down $12.16 during mid-day trading on Friday, hitting $469.00. The company had a trading volume of 971,940 shares, compared to its average volume of 1,573,249. The firm has a market cap of $120.78 billion, a P/E ratio of -235.68, a P/E/G ratio of 2.39 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The business's fifty day moving average is $435.84 and its two-hundred day moving average is $462.87. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same quarter last year, the firm earned $3.67 EPS. Vertex Pharmaceuticals's quarterly revenue was up 11.6% compared to the same quarter last year. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of a number of analyst reports. UBS Group upped their price target on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Wells Fargo & Company cut Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 target price for the company. in a research report on Thursday, January 30th. Barclays dropped their price target on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an "equal weight" rating on the stock in a research report on Friday, December 20th. Oppenheimer downgraded shares of Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Thursday, December 19th. Finally, BMO Capital Markets dropped their target price on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating on the stock in a report on Friday, December 20th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $502.58.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.